[253] 屈凤莲, 郝学志, 秦叔逵, 等. 亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究[J]. 中华肿瘤杂志, 2011, 33(9): 697-701. [254] Bruix J, Qin S, Merle P, et al. Regorafenib for
patients with hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J].
Lancet, 2017, 389(10064): 56-66. [255] Qin S, Li Q, Gu S, et al. Apatinib as
second-line or later therapy in patients with advanced hepatocellular carcinoma
(AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3
trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-68. [256] Qin S, Ren Z, Meng Z, et al. Camrelizumab in
patients with previously treated advanced hepatocellular carcinoma: a
multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet
Oncol, 2020, 21(4): 571-80. [257] Xu J, Shen J, Gu S, et al. Camrelizumab in
Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma
(RESCUE): A Nonrandomized, Open-label, Phase II Trial[J]. Clin Cancer Res,
2021, 27(4): 1003-11. [258] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 Antibody
SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric,
or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and
Expansion Study[J]. Clin Cancer Res, 2019, 25(2): 515-23. [259] Ducreux M, Abou-Alfa GK, Ren Z, et al. Results
from a global Phase 2 study of tislelizumab, an investigational PD-1 antibody,
in patients with previously treated advanced hepatocellular carcinoma[C]. ESMO
WCGI, 2021. [260] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab
in patients with advanced hepatocellular carcinoma previously treated with
sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet
Oncol, 2018, 19(7): 940-52. [261] Yau T, Kang YK, Kim TY, et al. Efficacy and
Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular
Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized
Clinical Trial[J]. JAMA Oncol, 2020, 6(11): e204564. [262] Abou-Alfa GK, Meyer T, Cheng AL, et al.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular
Carcinoma[J]. N Engl J Med, 2018, 379(1):54-63. [263] Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab
versus placebo as second-line treatment in patients with advanced
hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a
randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2015,
16(7): 859-70. [264] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab
after sorafenib in patients with advanced hepatocellular carcinoma and
increased alpha-fetoprotein concentrations (REACH-2): a randomised,
double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):
282-96. [265] 蔡定芳. 病证辨治创建中国中西结合临床医学体系[J]. 中国中西医结合杂志, 2019, 39(9): 1034-5. [266] 蔡定芳. 论病证结合临床诊疗模式[J]. 中国中西医结合杂志, 2019, 39(2):133-5. [267] Zhai XF, Liu XL, Shen F, et al. Traditional
herbal medicine prevents postoperative recurrence of small hepatocellular
carcinoma: A randomized controlled study[J]. Cancer, 2018, 124(10):2161-8. [268] Qin SK, Li Q, Ming Xu J, et al. Icaritin-induced
immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular
carcinoma: Immunodynamic biomarkers and overall survival[J]. Cancer Sci, 2020,
111(11): 4218-31. [269] Yu Z, Guo J, Hu M, et al. Icaritin Exacerbates
Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in
Hepatocellular Carcinoma[J]. ACS Nano, 2020, 14(4): 4816-28. [270] 蔡文辉, 尹春丽, 范庆秋. 艾迪联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J]. 中国医师杂志, 2018, 20(11): 1723-5. [271] 成远, 华海清. 榄香烯治疗原发性肝癌的研究进展[J]. 临床肿瘤学杂志, 2017, 22(10): 950-3. [272] 范隼, 李庆源, 周志涛, 等. TACE 联合金龙胶囊治疗原发性肝癌的效果研究[J]. 中国实用医药, 2019, 14(21): 42-4. [273] 高继良. 肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究[J]. 中国中药杂志, 2014, 39(12): 2367-9. [274] 路大鹏, 王玉强, 赵卫林, 等. 康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J]. 世界临床医学, 2017, 11(5): 70,2. [275] 杨新华. TACE联合鸦胆子油乳液静脉滴注对肝癌患者的临床疗效及VEGF水平的影响[J]. 海峡药学, 2017, 29(9): 176-7. [276] EASL Recommendations on Treatment of Hepatitis C
2018[J]. J Hepatol, 2018, 69(2): 461-511. [277] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019 年版)[J]. 中华传染病杂志, 2020, 38(1): 9-28. [278] 秦叔逵, 马军. 中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)[J]. 临床肿瘤学杂志, 2021, 26(7): 638-48. [279] 史艳侠, 邢镨元, 张俊, 等. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019 版)[J]. 中国肿瘤临床, 2019, (18): 923-9. [280] Seymour L, Bogaerts J, Perrone A, et al.
iRECIST: guidelines for response criteria for use in trials testing
immunotherapeutics[J]. Lancet Oncol, 2017, 18(3):e143-e52. [281] Moris D,
Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of
ruptured hepatocellular carcinoma: A systematic review[J]. J Surg Oncol, 2018,
117(3): 341-53. [282] Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of
Hepatocellular Carcinoma:A Review of Literature[J]. J Clin Exp Hepatol, 2019,
9(2): 245-56. [283] Tan NP, Majeed A, Roberts SK, et al. Survival of
patients with ruptured and non-ruptured hepatocellular carcinoma[J]. Med J
Aust, 2020, 212(6): 277-8. [284] Yoshida H, Mamada Y, Taniai N, et al.
Spontaneous ruptured hepatocellular carcinoma[J]. Hepatol Res, 2016, 46(1):
13-21. [285] Zhong F, Cheng XS, He K, et al. Treatment
outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic
shock: a multicenter study[J]. Springerplus, 2016, 5(1): 1101. [286] Aoki T, Kokudo N, Matsuyama Y, et al. Prognostic
impact of spontaneous tumor rupture in patients with hepatocellular carcinoma:
an analysis of 1160 cases from a nationwide survey[J]. Ann Surg, 2014, 259(3):
532-42. [287] Lai EC, Lau WY. Spontaneous rupture of
hepatocellular carcinoma: a systematic review[J]. Arch Surg, 2006, 141(2):
191-8. [288] Shin BS, Park MH, Jeon GS. Outcome and
prognostic factors of spontaneous ruptured hepatocellular carcinoma treated
with transarterial embolization[J]. Acta Radiol, 2011, 52(3): 331-5. [289] Roussel E, Bubenheim M, Le Treut YP, et al.
Peritoneal Carcinomatosis Risk and Long-Term Survival Following Hepatectomy for
Spontaneous Hepatocellular Carcinoma Rupture: Results of a Multicenter French
Study (FRENCH-AFC)[J]. Ann Surg Oncol, 2020, 27(9): 3383-92. [290] Zhou J, Huang A, Yang XR. Liquid Biopsy and its
Potential for Management of Hepatocellular Carcinoma[J]. J Gastrointest Cancer,
2016, 47(2): 157-67. [291] Guo W, Sun YF, Shen MN, et al. Circulating Tumor
Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic
Response Evaluation in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018,
24(9): 2203-13. [292] Zhou Y, Wang B, Wu J, et al. Association of
preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with
early recurrence of hepatocellular carcinoma following radical hepatic
resection[J]. BMC Cancer, 2016, 16: 506.
|
